FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Cryo-Save Bulgaria participated in the 5th National Conference of Obstetricians & Gynecologists from the Out-patient Setting, held on February 24-26 in Plovdiv, Bulgaria. read more
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces today that it has entered into an alliance with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire. read more
Abbott (NYSE: ABT) and Galapagos (Euronext: GLPG) announced today that they have entered into a global collaboration to develop and commercialize an oral, next-generation JAK1 inhibitor in Phase II development with the potential to treat multiple autoimmune diseases. read more
Devgen nv (Euronext Brussels: DEVG) today announces the successful completion of the first sales season of its first hybrid pearl millet seed adapted to all pearl millet growing areas in India. read more
Devgen nv (Euronext Brussels: DEVG) today announces the successful conclusion of farmer trials in India of two new premium hybrid rice varieties. Sales of these new products start in the upcoming planting season beginning in May 2012. read more
Applied Maths NV proudly reports that it has realized a growth in revenues of more than 14% in 2011. This growth is remarkable in view of the financial crisis and its negative impact on budget spending for research in particular. Applied Maths has realized a growth in all continents, including Europe and the US, the company's home markets for 20 years. read more
Ablynx (Euronext Brussels: ABLX), the Belgian-based biopharmaceutical company focused on the discovery and development of Nanobodies for the treatment of serious life-threatening diseases, today announced the Company's consolidated results for the year ending 31 December 2011, which have been prepared in accordance with IFRS as adopted by the European Union. read more